IMMUNICUM AB – Trademark Portfolio

Entity Type: 99

IMMUNICUM AB holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include MENDUS. The owner is based in GÖTEBORG.

Stena Center 1

GÖTEBORG 41292 , SE

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MENDUS
MENDUS
Registered 2022
INTUVAX
INTUVAX
Cancelled 2013
SUBCUVAX
SUBCUVAX
Cancelled 2013
INTUVAC
INTUVAC
Abandoned 2012

Trademark Classifications

IMMUNICUM AB's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (5 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does IMMUNICUM AB have?

IMMUNICUM AB has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 2 cancelled.

What trademark classes does IMMUNICUM AB file in?

IMMUNICUM AB files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are IMMUNICUM AB's most well-known trademarks?

IMMUNICUM AB's registered trademark portfolio includes well-known marks such as MENDUS. These are among 1 currently registered trademark in the portfolio.

What is IMMUNICUM AB's trademark registration success rate?

IMMUNICUM AB has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.